UNLABELLED: The aim of this study is to evaluate the humoral autoimmune response in the experimental model of systemic sclerosis (SSc) induced by human type V collagen (huCol V). New Zealand rabbits were immunized with huCol V in Freund's complete adjuvant (FCA) and boosted twice with 15 days intervals with huCol V in Freund's incomplete adjuvant. Control groups included animals injected only with FCA or bovine serum albumin. Bleeding was done at days 0, 30, 75 and 120. Tissue specimens were obtained for histopathological investigation. Serological analysis included detection of antibodies against huCol V and anti-topoisomerase I (Anti-Scl70) by enzyme-linked immunosorbent assay, antinuclear antibodies (ANA) by indirect immunofluorescence, and rheumatoid factor (RF) by a latex agglutination test. Target antigens were characterized by immunoblot. Histological analysis revealed extracellular matrix remodeling with fibrosis and vasculitis. Anti-Scl70 and ANA were detected as early as 30 days in all huCol V animals. The universal ANA staining pattern was Golgi-like. This serum reactivity was not abolished by previous absorption with huCol V. Characterization of the target antigen by immunoblot revealed two major protein fractions of 175,000 and 220,000 MW. Similarly to ANA, there was a gradual increase of reactivity throughout the immunization and also it was not abolished by preincubation of serum samples with huCol V. RF testing was negative in hyperimmune sera. CONCLUSION: The production of autoantibodies, including anti-Scl70, a serological marker for SSc associated with histopathological alterations, validates huCol V induced-experimental model and brings out its potential for understanding the pathophysiology of SSc.
UNLABELLED: The aim of this study is to evaluate the humoral autoimmune response in the experimental model of systemic sclerosis (SSc) induced by human type V collagen (huCol V). New Zealand rabbits were immunized with huCol V in Freund's complete adjuvant (FCA) and boosted twice with 15 days intervals with huCol V in Freund's incomplete adjuvant. Control groups included animals injected only with FCA or bovine serum albumin. Bleeding was done at days 0, 30, 75 and 120. Tissue specimens were obtained for histopathological investigation. Serological analysis included detection of antibodies against huCol V and anti-topoisomerase I (Anti-Scl70) by enzyme-linked immunosorbent assay, antinuclear antibodies (ANA) by indirect immunofluorescence, and rheumatoid factor (RF) by a latex agglutination test. Target antigens were characterized by immunoblot. Histological analysis revealed extracellular matrix remodeling with fibrosis and vasculitis. Anti-Scl70 and ANA were detected as early as 30 days in all huCol V animals. The universal ANA staining pattern was Golgi-like. This serum reactivity was not abolished by previous absorption with huCol V. Characterization of the target antigen by immunoblot revealed two major protein fractions of 175,000 and 220,000 MW. Similarly to ANA, there was a gradual increase of reactivity throughout the immunization and also it was not abolished by preincubation of serum samples with huCol V. RF testing was negative in hyperimmune sera. CONCLUSION: The production of autoantibodies, including anti-Scl70, a serological marker for SSc associated with histopathological alterations, validates huCol V induced-experimental model and brings out its potential for understanding the pathophysiology of SSc.
Authors: Walcy R Teodoro; Beatriz G Miron; Luciana Tsuzuki; Ichicawa Ogido; Ana P Velosa; Fátima Abatepaulo; Vera L Capelozzi; Natalino H Yoshinari Journal: Pathol Res Pract Date: 2003 Impact factor: 3.250
Authors: Edwin Roger Parra; Walcy R Teodoro; Ana Paula Pereira Velosa; Cristiane Carla de Oliveira; Natalino Hajime Yoshinari; Vera Luiza Capelozzi Journal: J Histochem Cytochem Date: 2006-08-21 Impact factor: 2.479
Authors: Charles A P Godoy; Walcy R Teodoro; Ana Paula P Velosa; Ana Lucia Garippo; Esmeralda Miristeni Eher; Edwin Roger Parra; Mirian N Sotto; Vera L Capelozzi Journal: Clinics (Sao Paulo) Date: 2015-05-01 Impact factor: 2.365
Authors: Silvana Ramos Atayde; Ana Paula Pereira Velosa; Sergio Catanozi; Vanessa Del Bianco; Priscila Cristina Andrade; José Eduardo de Castro M Rodrigues; Antonio Dos Santos Filho; Leila Antonangelo; Suzana Beatriz Veríssimo de Mello; Vera Luiza Capelozzi; Walcy Rosolia Teodoro Journal: PLoS One Date: 2018-07-30 Impact factor: 3.240
Authors: Ana Paula Pereira Velosa; Lais Brito; Zelita Aparecida de Jesus Queiroz; Solange Carrasco; Jurandir Tomaz de Miranda; Cecília Farhat; Cláudia Goldenstein-Schainberg; Edwin Roger Parra; Danieli Castro Oliveira de Andrade; Pedro Leme Silva; Vera Luiza Capelozzi; Walcy Rosolia Teodoro Journal: Front Immunol Date: 2021-02-12 Impact factor: 7.561
Authors: Ana Paula P Velosa; Walcy R Teodoro; Daniel M dos Anjos; Renata Konno; Cristiane C Oliveira; Maria L H Katayama; Edwin R Parra; Vera L Capelozzi; Natalino H Yoshinari Journal: Respir Res Date: 2010-01-04
Authors: Walcy Rosolia Teodoro; Zelita Aparecida de Jesus Queiroz; Lais Araujo Dos Santos; Sergio Catanozi; Antonio Dos Santos Filho; Cleonice Bueno; Margarete B G Vendramini; Sandra de Morais Fernezlian; Esmeralda M Eher; Percival D Sampaio-Barros; Sandra Gofinet Pasoto; Fernanda Degobbi T Q S Lopes; Ana Paula Pereira Velosa; Vera Luiza Capelozzi Journal: Arthritis Res Ther Date: 2019-12-11 Impact factor: 5.156